This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clovis Oncology マネジメント

マネジメント基準チェック /34

Clovis Oncologyの CEO はPatrick Mahaffyで、 Apr2009年に任命され、の在任期間は 14.25年です。は、会社の株式の0.67%を直接所有しており、その価値は€ 14.56K 。経営陣と取締役会の平均在任期間はそれぞれ7.4年と14.3年です。

主要情報

Patrick Mahaffy

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	14.3yrs
CEOの所有権	0.7%
経営陣の平均在職期間	7.4yrs
取締役会の平均在任期間	14.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Clovis Oncology の収益と比較して、Patrick Mahaffy の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2022	n/a	n/a	-US$252m
Jun 30 2022	n/a	n/a	-US$263m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$3m	US$739k	-US$265m
Sep 30 2021	n/a	n/a	-US$299m
Jun 30 2021	n/a	n/a	-US$310m
Mar 31 2021	n/a	n/a	-US$336m
Dec 31 2020	US$3m	US$721k	-US$369m
Sep 30 2020	n/a	n/a	-US$370m
Jun 30 2020	n/a	n/a	-US$385m
Mar 31 2020	n/a	n/a	-US$413m
Dec 31 2019	US$7m	US$719k	-US$400m
Sep 30 2019	n/a	n/a	-US$400m
Jun 30 2019	n/a	n/a	-US$396m
Mar 31 2019	n/a	n/a	-US$377m
Dec 31 2018	US$6m	US$689k	-US$368m
Sep 30 2018	n/a	n/a	-US$321m
Jun 30 2018	n/a	n/a	-US$291m
Mar 31 2018	n/a	n/a	-US$366m
Dec 31 2017	US$9m	US$636k	-US$346m
Sep 30 2017	n/a	n/a	-US$365m
Jun 30 2017	n/a	n/a	-US$370m
Mar 31 2017	n/a	n/a	-US$324m
Dec 31 2016	US$789k	US$224k	-US$349m

報酬と市場: Patrickの総報酬がGerman市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Patrickの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Patrick Mahaffy (60 yo)

14.3yrs

在職期間

US$2,639,083

報酬

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Patrick Mahaffy	Co-Founder	14.3yrs	US$2.64m	0.67% € 14.6k
Daniel Muehl	Executive VP & CFO	7.3yrs	US$1.19m	0.072% € 1.6k
Paul Gross	Executive VP	7.5yrs	US$1.20m	0.068% € 1.5k
Lindsey Rolfe	Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer	7.9yrs	US$1.24m	0.078% € 1.7k
Thomas Harding	Executive VP & Chief Scientific Officer	3.8yrs	データなし	データなし
Ann Bozeman	Executive Vice President of Human Resources	6.8yrs	データなし	データなし

7.4yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: C6Oの経営陣は経験豊富で経験豊富です（平均在職期間は7.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Patrick Mahaffy	Co-Founder	14.3yrs	US$2.64m	0.67% € 14.6k
Paul Klingenstein	Independent Director	14.3yrs	US$260.00k	0.041% € 889.9
Brian Atwood	Independent Director	14.5yrs	US$270.00k	0.040% € 875.1
Edward McKinley	Independent Director	14.5yrs	US$270.00k	0.17% € 3.8k
James Blair	Independent Director	14.5yrs	US$270.00k	0.044% € 953.2
Ginger Graham	Independent Chairman	10.5yrs	US$287.50k	0% € 0
Thorlef Spickschen	Independent Director	14.5yrs	US$257.50k	0.040% € 872.7
Ronit Simantov	Director	2yrs	US$375.21k	データなし
Keith Flaherty	Independent Director	10.5yrs	US$259.58k	0% € 0
Richard Fair	Independent Director	4.8yrs	US$257.50k	0% € 0
Robert Azelby	Independent Director	4.8yrs	US$255.00k	0% € 0

14.3yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: C6Oの取締役会は経験豊富で経験豊富です ( 14.3年の平均在任期間)。

This company listing is no longer active

Clovis Oncology マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Revenue beats expectations

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €7.51

New 90-day high: €4.99

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.84

Clovis Oncology, Inc. to Report Q1, 2020 Results on May 05, 2020

Clovis Oncology, Inc. Presents Highlight Breadth and Potential of Clovis Oncology Products and Pipeline At ESMO Virtual Congress 2020

First half earnings released

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34